Evolving Companion Diagnostics: From Targeted Markers to Full-Stack Multi-Omic Partnerships

  • Beyond the Biomarker: From reactive testing to platform-driven strategy
  • Partnering from IND to Launch: Diagnostics as a strategic asset
  • Unlocking RNA and proteomics for IO, ADCs, and emerging modalities